Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Paediatric proteomic signatures of cardiometabolic disease-associated traits predict adult disease outcomes.

Created on 12 Sep 2026

Authors

Joshua M Landman, Heather M Highland, Andrew S Perry, Annie G Howard, Quanhu Sheng, Anna Lorenz, Alexandra B Palmer, Shilin Zhao, Wanying Zhu, Xinruo Zhang, Victoria L Buchanan, Elizabeth G Frankel, Rashedeh Roshani, Alyssa Scartozzi, Eric H Farber-Eger, Mohammad Y Anwar, Jessica K Sprinkles, Ash Breidenbach, Ting-Chen Wang, Christine A Ballard, Matthew Nayor, Jaclyn Tamaroff, Absalon Gutierrez, Lauren E Petty, Alexander S Petty, Benjamin Lippi, Lindsay Fernandez-Rhodes, Hung-Hsin Chen, Mohanraj Krishnan, Mariaelisa Graff, Katie A Meyer, Miryoung Lee, Kristin L Young, Quinn Wells, Kahraman Tanriverdi, Jane E Freedman, Eric R Gamazon, Joseph B McCormick, Susan P Fisher-Hoch, Penny Gordon-Larsen, Jennifer E Below, Kari E North, Ravi V Shah

Published in

Nature metabolism. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

While the earliest pathological signs of cardiovascular-kidney-metabolic disease (CKMD) emerge before age 20, current adult-based risk thresholds fail to identify a substantial fraction of children at high risk. With increasing childhood obesity, early, sensitive detection of CKMD risk is critical to timely intervention. We linked 25 CKMD phenotypes spanning liver, adipose, vascular and dysglycaemia traits to the circulating proteome in 273 Hispanic or Latino children and adolescents (13.1 ± 2.7 years; 53% female). Here we show that proteome signatures of CKMD in children are strongly associated with clinical CKMD outcomes in adults. In 685 adults from the same community and 28,256 adults from UK Biobank, we observe high concordance between the paediatric and adult CKMD phenotype-proteome relationships, related to pancreatic beta-cell health and insulin sensitivity, liver homeostasis, inflammation and cholesterol metabolism. Many proteins linked to paediatric CKMD were modifiable with glucagon-like peptide-1 receptor agonist therapy in adults and are linked to genetic liability to CKMD. These findings support an early origin of CKMD disease liability embedded in the human proteome in children, underscoring the value of precision prevention to forestall metabolic disease long before its clinical manifestation.

PMID:
42728365
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement